These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 37460968)

  • 1. Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension.
    Krajnc N; Itariu B; Macher S; Marik W; Harreiter J; Michl M; Novak K; Wöber C; Pemp B; Bsteh G
    J Headache Pain; 2023 Jul; 24(1):89. PubMed ID: 37460968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effect of a single lumbar puncture in idiopathic intracranial hypertension.
    Zaic S; Krajnc N; Macher S; Michl M; Müller N; Mitsch C; Marik W; Novak K; Wöber C; Pemp B; Bsteh G
    J Headache Pain; 2024 Sep; 25(1):145. PubMed ID: 39237912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial.
    ; Wall M; McDermott MP; Kieburtz KD; Corbett JJ; Feldon SE; Friedman DI; Katz DM; Keltner JL; Schron EB; Kupersmith MJ
    JAMA; 2014 Apr 23-30; 311(16):1641-51. PubMed ID: 24756514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idiopathic Intracranial Hypertension After Abrupt Cessation of Medication: A Case Report of Abrupt Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Cessation and Review of the Literature.
    Heckel B
    Curr Pain Headache Rep; 2024 Jun; 28(6):453-456. PubMed ID: 38573570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.
    Liu L; Chen J; Wang L; Chen C; Chen L
    Front Endocrinol (Lausanne); 2022; 13():1043789. PubMed ID: 36568085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women.
    Iepsen EW; Lundgren JR; Hartmann B; Pedersen O; Hansen T; Jørgensen NR; Jensen JE; Holst JJ; Madsbad S; Torekov SS
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2909-17. PubMed ID: 26043228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li Y; Rosenblit PD
    Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised controlled trial of bariatric surgery versus a community weight loss programme for the sustained treatment of idiopathic intracranial hypertension: the Idiopathic Intracranial Hypertension Weight Trial (IIH:WT) protocol.
    Ottridge R; Mollan SP; Botfield H; Frew E; Ives NJ; Matthews T; Mitchell J; Rick C; Singhal R; Woolley R; Sinclair AJ
    BMJ Open; 2017 Sep; 7(9):e017426. PubMed ID: 28963303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should topiramate be initial therapy in the management of idiopathic intracranial hypertension?: A literature review.
    Goyal A; Zarroli K
    Medicine (Baltimore); 2023 Oct; 102(42):e35545. PubMed ID: 37861536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erenumab for headaches in idiopathic intracranial hypertension: A prospective open-label evaluation.
    Yiangou A; Mitchell JL; Fisher C; Edwards J; Vijay V; Alimajstorovic Z; Grech O; Lavery GG; Mollan SP; Sinclair AJ
    Headache; 2021 Jan; 61(1):157-169. PubMed ID: 33316102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reprint of: Impact of a pharmacist-led weight management service in a cardiology clinic.
    Yates M; Supple M; Maccia M
    J Am Pharm Assoc (2003); 2024; 64(4S):102157. PubMed ID: 39127937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study.
    Takeshita Y; Kita Y; Tanaka T; Goto H; Nakano Y; Teramura C; Enyama Y; Takamura T;
    J Diabetes Investig; 2022 Jun; 13(6):965-974. PubMed ID: 35034428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials.
    Alkhezi OS; Alahmed AA; Alfayez OM; Alzuman OA; Almutairi AR; Almohammed OA
    Obes Rev; 2023 Mar; 24(3):e13543. PubMed ID: 36579723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
    O'Neil PM; Birkenfeld AL; McGowan B; Mosenzon O; Pedersen SD; Wharton S; Carson CG; Jepsen CH; Kabisch M; Wilding JPH
    Lancet; 2018 Aug; 392(10148):637-649. PubMed ID: 30122305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
    Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
    Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US.
    Eberly LA; Yang L; Essien UR; Eneanya ND; Julien HM; Luo J; Nathan AS; Khatana SAM; Dayoub EJ; Fanaroff AC; Giri J; Groeneveld PW; Adusumalli S
    JAMA Health Forum; 2021 Dec; 2(12):e214182. PubMed ID: 35977298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear Magnetic Resonance Spectroscopy Metabolomics in Idiopathic Intracranial Hypertension to Identify Markers of Disease and Headache.
    Grech O; Seneviratne SY; Alimajstorovic Z; Yiangou A; Mitchell JL; Smith TB; Mollan SP; Lavery GG; Ludwig C; Sinclair AJ
    Neurology; 2022 Oct; 99(16):e1702-e1714. PubMed ID: 36240084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
    He L; Wang J; Ping F; Yang N; Huang J; Li Y; Xu L; Li W; Zhang H
    JAMA Intern Med; 2022 May; 182(5):513-519. PubMed ID: 35344001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.